Atherosclerosis
Volume 205, Issue 1 , Pages 296-301, July 2009

Omega-3 fatty acids improve postprandial lipaemia in patients with nephrotic range proteinuria

  • Samira Bell

      Affiliations

    • Renal Unit, Walton Building, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, United Kingdom
    • Corresponding Author InformationCorresponding author. Tel.: +44 141 211 0570; fax: +44 141 211 4843.
  • ,
  • Josephine Cooney

      Affiliations

    • Department of Vascular Biochemistry, Glasgow Royal Infirmary Glasgow, United Kingdom
  • ,
  • Christopher J. Packard

      Affiliations

    • Department of Vascular Biochemistry, Glasgow Royal Infirmary Glasgow, United Kingdom
  • ,
  • Muriel Caslake

      Affiliations

    • Department of Vascular Biochemistry, Glasgow Royal Infirmary Glasgow, United Kingdom
  • ,
  • Christopher J. Deighan

      Affiliations

    • Renal Unit, Walton Building, Glasgow Royal Infirmary, Castle Street, Glasgow G4 0SF, United Kingdom

Received 1 July 2008; received in revised form 24 November 2008; accepted 1 December 2008. published online 16 January 2009.

Abstract 

Background

Patients with nephrotic range proteinuria have a marked increase in the risk of cardiovascular disease. Qualitative and quantitative changes in lipids and lipoproteins contribute to this increased risk with an abundance of atherogenic triglyceride (TG) rich apolipoprotein B containing lipoproteins. TG rich lipoproteins predominate postprandially and are associated with increased risk of coronary heart disease (CHD). Omega-3 fatty acids derived from fish oils have been shown to have beneficial effects on lipids and lipoproteins in patients without proteinuria.

Methods

17 patients with nephrotic range proteinuria and 17 age and sex matched controls were studied. Postprandial lipaemia was assessed in patients and controls, before and after 8 weeks treatment with 4g daily of omega-3 fatty acids (Omacor). A standard fat load (90g) was administered and blood sampling was performed in the fasting state and at 2, 4, 6 and 8h after the fat load. Chylomicrons and VLDL1 density fraction was isolated from plasma by density ultracentrifugation. Postprandial chylomicron and VLDL1 triglyceride concentrations were measured and quantified using the incremental area under the curve (AUC) method.

Results

Baseline postprandial chylomicron TG AUC was greater in patients compared with controls: median 18.5mmol/lh (interquartile range 8.9–32.6) vs 9.3mmol/lh (4.8–14.4) p=0.05. Following treatment patient chylomicron AUC fell [mean reduction 6.8mmol/lh (95% CI 0.1–13.6) p=0.05]. No significant reduction in chylomicron AUC was observed in the controls [mean reduction 3.9mmol/lh (95% CI −3.6 to 11.5)]. As a result, following 8 weeks treatment with omega-3 fatty acids, patient and control chylomicron AUC were no longer significantly different [patients 13.5mmol/lh (7.4–22.9), controls 7.2mmol/lh (4.6–14.5) both median and IQR, p=nsd]. VLDL1 TG AUC did not differ at baseline between patients and controls. Furthermore, there was no significant effect on VLDL1 AUC following treatment in either group.

Conclusions

We have shown that there is an excess of postprandial chylomicron density fraction in patients with nephrotic range proteinuria, which is reduced by treatment with omega-3 fatty acids. We suggest that this would be an ideal therapy in combination with statins for this high risk group of patients.

Keywords: Lipids, Lipoproteins, Nephrotic, Omega-3 fatty acids, Postprandial lipaemia

To access this article, please choose from the options below

Login to an existing account or Register a new account.

  • Purchase this article for 31.50 USD (You must login/register to purchase this article)

    Online access for 24 hours. The PDF version can be downloaded as your permanent record.

  • Subscribe to this title

    Get unlimited online access to this article and all other articles in this title 24/7 for one year.

  • Claim access now

    For current subscribers with Society Membership or Account Number.

  • Visit SciVerse ScienceDirect to see if you have access via your institution.
 

PII: S0021-9150(08)00844-7

doi:10.1016/j.atherosclerosis.2008.12.002

Atherosclerosis
Volume 205, Issue 1 , Pages 296-301, July 2009